Migdal Insurance & Financial Holdings Ltd. Acquires Shares of 1,050,000 Cellebrite DI Ltd. $CLBT

Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) during the third quarter, HoldingsChannel reports. The firm bought 1,050,000 shares of the company’s stock, valued at approximately $19,457,000.

Several other institutional investors also recently modified their holdings of the business. Voss Capital LP lifted its position in Cellebrite DI by 34.0% during the 2nd quarter. Voss Capital LP now owns 5,150,000 shares of the company’s stock valued at $82,400,000 after acquiring an additional 1,306,398 shares during the period. Clal Insurance Enterprises Holdings Ltd grew its holdings in Cellebrite DI by 17.1% in the second quarter. Clal Insurance Enterprises Holdings Ltd now owns 3,913,014 shares of the company’s stock worth $62,608,000 after purchasing an additional 570,000 shares during the period. Invesco Ltd. increased its stake in shares of Cellebrite DI by 6.4% during the second quarter. Invesco Ltd. now owns 3,505,552 shares of the company’s stock valued at $56,089,000 after purchasing an additional 209,473 shares in the last quarter. Pertento Partners LLP lifted its holdings in shares of Cellebrite DI by 11.8% during the second quarter. Pertento Partners LLP now owns 2,945,641 shares of the company’s stock valued at $47,130,000 after purchasing an additional 309,988 shares during the last quarter. Finally, Handelsbanken Fonder AB boosted its position in shares of Cellebrite DI by 61.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 2,450,000 shares of the company’s stock worth $39,200,000 after purchasing an additional 931,300 shares in the last quarter. 45.88% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on CLBT shares. Bank of America raised their price objective on Cellebrite DI from $24.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. JPMorgan Chase & Co. raised their price target on Cellebrite DI from $23.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, November 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cellebrite DI in a research report on Monday, December 29th. Wall Street Zen cut shares of Cellebrite DI from a “buy” rating to a “hold” rating in a research note on Saturday, November 8th. Finally, Lake Street Capital raised their price objective on shares of Cellebrite DI from $22.00 to $23.00 and gave the company a “buy” rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Cellebrite DI presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.00.

Cellebrite DI Price Performance

Cellebrite DI stock opened at $16.38 on Wednesday. Cellebrite DI Ltd. has a one year low of $13.10 and a one year high of $26.30. The business’s fifty day moving average is $17.97 and its 200 day moving average is $16.97. The stock has a market capitalization of $3.92 billion, a PE ratio of 52.84, a price-to-earnings-growth ratio of 2.37 and a beta of 1.28.

Cellebrite DI (NASDAQ:CLBT) last announced its quarterly earnings results on Wednesday, November 12th. The company reported $0.08 EPS for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.05). The company had revenue of $126.03 million during the quarter, compared to the consensus estimate of $122.98 million. Cellebrite DI had a return on equity of 20.81% and a net margin of 16.74%.The business’s revenue was up 17.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.14 earnings per share. As a group, sell-side analysts expect that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.